Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
相关临床试验
18
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
2
11.1%
已完成
7
38.9%
招募中
2
11.1%
暂停
1
5.6%
终止
4
22.2%
Unknown
2
11.1%
暂无批准数据
- Independent researchers found that biliary tract cancer cell lines demonstrated sensitivity to plogosertib, a PLK1 inhibitor, both as monotherapy and in combination treatments. - The study identified BUBR1 as a potential biomarker, with cancer cells showing high BUBR1 expression being more sensitive to plogosertib treatment. - Plogosertib showed synergistic effects when combined with ATR inhibitors, suggesting a promising therapeutic strategy for treating this aggressive cancer with poor prognosis. - Early Phase 1 clinical data indicate plogosertib is well-tolerated with no dose-limiting toxicity observed across five dosing schedules.
- Cyclacel Pharmaceuticals completed enrollment in Cohort 8 of its Phase 2 trial of fadraciclib, a CDK2/9 inhibitor, focusing on patients with advanced solid tumors and lymphoma exhibiting CDKN2A/B abnormalities. - The rapid enrollment, completed in approximately six months, highlights the significant unmet need for cancer patients with these specific genetic aberrations. - Early data from the trial shows promising signs of stable disease and tumor shrinkage in a squamous cell cancer patient with CDKN2A abnormalities after treatment with oral fadraciclib. - Updated safety and efficacy data from the trial will be presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) in October.
